BRIEF-Merck says FDA approves Keytruda(pembrolizumab) for previously treated patients

* Fda approves Merck’s keytruda® (pembrolizumab) for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express pd-l1 (cps greater than or equal to 1)